Evidence map›Paper›PMID 42573617›Full record

ArticleMedicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents2026

Novel sulfonylhydrazide anacardic acid derivatives as potent α-glucosidase inhibitors: Synthesis, crystal structure, biological evaluation, and computational studies.

Van-Can Pham, Thammarat Aree, Aamir Aman, Thanyada Rungrotmongkol, Warinthorn Chavasiri

Abstract read
PubMed Publisher
In one paragraph

Article in Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Van-Can PhamCenter of Excellence in Natural Products Chemistry, Department of Chemistry, Faculty of Science, Chulalongkorn University, Pathumwan, Bangkok, 10330, Thailand.
Thammarat AreeDepartment of Chemistry, Faculty of Science, Chulalongkorn University, Pathumwan, Bangkok, 10330, Thailand.
Aamir AmanProgram in Bioinformatics and Computational Biology, College of Interdisciplinary and Integrative Studies, Chulalongkorn University, Bangkok, 10330, Thailand.
Thanyada RungrotmongkolProgram in Bioinformatics and Computational Biology, College of Interdisciplinary and Integrative Studies, Chulalongkorn University, Bangkok, 10330, Thailand.
Warinthorn ChavasiriCenter of Excellence in Natural Products Chemistry, Department of Chemistry, Faculty of Science, Chulalongkorn University, Pathumwan, Bangkok, 10330, Thailand. warinthorn.c@chula.ac.th.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inhibiting α-glucosidase (AG) enzyme is recognized as a key therapeutic approach for diabetes treatment. Nine saturated anacardic acid derivatives (2-10) were synthesized, well-characterized, and evaluated for their inhibitory activity against AG. All six sulfonylhydrazide saturated anacardic acid analogues (5-10) were disclosed as novel compounds, and their structures were endorsed by NMR spectroscopy, X-ray crystallography, and mass spectrometry. They exhibited strong inhibition against AG with IC

Indexed as

alpha-GlucosidasesAnacardic AcidsGlycoside Hydrolase InhibitorsHydrazinesCrystallography, X-RayHumansMolecular Docking SimulationMolecular StructureStructure-Activity Relationshipalpha-Glucosidasesanacardic acidAnacardic AcidsGlycoside Hydrolase InhibitorsHydrazinesAnacardic acidCrystallizationMolecular dockingSulfonylhydrazideVisualization analysis.α-Glucosidase inhibitor

Identifiers

PMID42573617

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.